Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 420

1.

Antiretroviral penetration across three preclinical animal models and humans in eight putative HIV viral reservoirs.

Devanathan AS, Pirone JR, Akkina R, Remling-Mulder L, Luciw P, Adamson L, Garcia JV, Kovarova M, White NR, Schauer AP, Blake K, Sykes C, Burgunder EM, Srinivas N, Rosen EP, Kashuba ADM.

Antimicrob Agents Chemother. 2019 Oct 14. pii: AAC.01639-19. doi: 10.1128/AAC.01639-19. [Epub ahead of print]

PMID:
31611355
2.

Pneumonia Prevention Strategies for Children With Neurologic Impairment.

Lin JL, Van Haren K, Rigdon J, Saynina O, Song H, Buu MC, Thakur Y, Srinivas N, Asch SM, Sanders LM.

Pediatrics. 2019 Oct;144(4). pii: e20190543. doi: 10.1542/peds.2019-0543. Epub 2019 Sep 19.

PMID:
31537634
3.

Role of Ceramides in Drug Delivery.

Alrbyawi H, Poudel I, Dash RP, Srinivas NR, Tiwari AK, Arnold RD, Babu RJ.

AAPS PharmSciTech. 2019 Aug 13;20(7):287. doi: 10.1208/s12249-019-1497-6.

PMID:
31410612
4.

Relationship of telomere length in colorectal cancer patients with cancer phenotype and patient prognosis.

Kroupa M, Rachakonda SK, Liska V, Srinivas N, Urbanova M, Jiraskova K, Schneiderova M, Vycital O, Vymetalkova V, Vodickova L, Kumar R, Vodicka P.

Br J Cancer. 2019 Aug;121(4):344-350. doi: 10.1038/s41416-019-0525-3. Epub 2019 Jul 17.

PMID:
31312029
5.

Use of sorbitol as pharmaceutical excipient in the present day formulations - issues and challenges for drug absorption and bioavailability.

Dash RP, Srinivas NR, Babu RJ.

Drug Dev Ind Pharm. 2019 Sep;45(9):1421-1429. doi: 10.1080/03639045.2019.1640722.

PMID:
31271324
6.

Combination of flavonoids with azole drugs for fungal infections: key pharmacokinetic challenges.

Srinivas NR.

Future Microbiol. 2019 Jun;14:733-738. doi: 10.2217/fmb-2019-0109. Epub 2019 Jul 4. No abstract available.

PMID:
31271062
7.

An Improvement Effort to Optimize Electronically Generated Hospital Discharge Instructions.

Chadwick W, Bassett H, Hendrickson S, Slonaker K, Perales S, Pantaleoni J, Srinivas N, Platchek T, Destino L.

Hosp Pediatr. 2019 Jul;9(7):523-529. doi: 10.1542/hpeds.2018-0251.

PMID:
31243058
8.

Comment on: Pharmacokinetics and Safety of Recombinant Human Interleukin-1 Receptor Antagonist GR007 in Healthy Chinese Subjects.

Srinivas NR.

Eur J Drug Metab Pharmacokinet. 2019 Oct;44(5):719-721. doi: 10.1007/s13318-019-00566-8. No abstract available.

PMID:
31240570
9.

Pharmacokinetic evaluation of differential drug release formulations of rabeprazole in dogs.

Patel H, Desai N, Patel P, Modi N, Soni K, Patel JR, Mistry GN, Patel JD, Chawla M, Srinivas NR.

Drug Dev Ind Pharm. 2019 Sep;45(9):1459-1467. doi: 10.1080/03639045.2019.1628249. Epub 2019 Jun 20.

PMID:
31216902
10.

Prediction of Human Pharmacokinetics of Fomepizole from Preclinical Species Pharmacokinetics Based on Normalizing Time Course Profiles.

Jairam RK, Mallurwar SR, Sulochana SP, Chandrasekhar DV, Todmal U, Bhamidipati RK, Richter W, Srinivas NR, Mullangi R.

AAPS PharmSciTech. 2019 Jun 18;20(6):221. doi: 10.1208/s12249-019-1434-8.

PMID:
31214899
11.

Simultaneous determination of bendamustine and γ-hydroxybendamustine in mice dried blood spots and its application in a mice pharmacokinetic study.

Kumar Saini N, Sulochana SP, Kiran V, Rangnathrao Mallurwar S, Richter W, Srinivas NR, Mullangi R.

J Pharm Biomed Anal. 2019 Sep 10;174:168-174. doi: 10.1016/j.jpba.2019.05.052. Epub 2019 May 28.

PMID:
31170630
12.

Uptake and pharmacokinetics of cefuroxime in rabbits after intravitreal, intracameral, and topical dosing: relevance to human ocular injection of cefuroxime.

Jairam RK, Mallurwar SR, Gabani BB, Zakkula A, Kiran V, Dittakavi S, Sulochana SP, Mohd Z, Srinivas NR, Mullangi R.

Xenobiotica. 2019 Jun 19:1-7. doi: 10.1080/00498254.2019.1624872. [Epub ahead of print]

PMID:
31144563
13.

Stereoselective pharmacokinetics and tissue distribution of levodropropizine after administration of pure levodropropizine and the rac-dropropizine to Sprague-Dawley rats.

Gabani BB, Todmal U, Saini NK, Balakrishna VA, Sulochana SP, Timmapuram A, Zainuddin M, Balaji N, Shuvranshu P, Srinivas NR, Mullangi R.

Xenobiotica. 2019 Mar 21:1-10. doi: 10.1080/00498254.2019.1599148. [Epub ahead of print]

PMID:
30896275
14.

Telomere length, arsenic exposure and risk of basal cell carcinoma of skin.

Srinivas N, Rachakonda S, Hielscher T, Calderazzo S, Rudnai P, Gurzau E, Koppova K, Fletcher T, Kumar R.

Carcinogenesis. 2019 Jul 6;40(6):715-723. doi: 10.1093/carcin/bgz059.

PMID:
30874287
15.

Targeting DNA Gyrase to Combat Mycobacterium tuberculosis: An Update.

Das S, Garg T, Srinivas N, Dasgupta A, Chopra S.

Curr Top Med Chem. 2019;19(8):579-593. doi: 10.2174/1568026619666190304130218. Review.

PMID:
30834837
16.

Predicting Efavirenz Concentrations in the Brain Tissue of HIV-Infected Individuals and Exploring their Relationship to Neurocognitive Impairment.

Srinivas N, Joseph SB, Robertson K, Kincer LP, Menezes P, Adamson L, Schauer AP, Blake KH, White N, Sykes C, Luciw P, Eron JJ, Forrest A, Price RW, Spudich S, Swanstrom R, Kashuba ADM.

Clin Transl Sci. 2019 May;12(3):302-311. doi: 10.1111/cts.12620. Epub 2019 Feb 27.

17.

Lack of inhibition of CYP2C8 by saroglitazar magnesium: In vivo assessment using montelukast, rosiglitazone, pioglitazone, repaglinide and paclitaxel as victim drugs in Wistar rats.

Giri P, Delvadia P, Ladani MK, Prajapati N, Gupta L, Patel N, Joshi V, Giri S, Jain MR, Srinivas NR, Patel PR.

Eur J Pharm Sci. 2019 Mar 15;130:107-113. doi: 10.1016/j.ejps.2019.01.005. Epub 2019 Jan 8.

PMID:
30633968
18.

Comment on: Pharmacokinetics, Pharmacodynamics, and Safety of the Novel Calcimimetic Agent Evocalcet in Healthy Japanese Subjects: First-in-Human Phase I Study.

Srinivas NR.

Clin Drug Investig. 2019 Jan;39(1):105-107. doi: 10.1007/s40261-018-0738-x. No abstract available.

PMID:
30632108
19.

Differential pharmacokinetic drug-drug interaction potential of eletriptan between oral and subcutaneous routes.

Patel H, Desai N, Patel P, Modi N, Soni K, Dobaria N, Srinivas NR.

Xenobiotica. 2019 Oct;49(10):1202-1208. doi: 10.1080/00498254.2018.1540805. Epub 2018 Dec 27.

PMID:
30588869
20.

Author Correction: Telomere length and survival in primary cutaneous melanoma patients.

Rachakonda S, Srinivas N, Mahmoudpour SH, Garcia-Casado Z, Requena C, Traves V, Soriano V, Cardelli M, Pjanova D, Molven A, Gruis N, Nagore E, Kumar R.

Sci Rep. 2018 Dec 14;8(1):17963. doi: 10.1038/s41598-018-36657-w.

21.

Review of DBS methods as a quantitative tool for anticancer drugs.

Sulochana SP, Daram P, Srinivas NR, Mullangi R.

Biomed Chromatogr. 2019 Jan;33(1):e4445. doi: 10.1002/bmc.4445. Review.

PMID:
30512220
22.

Assessment of the in vitro cytochrome P450 (CYP) inhibition potential of ZYTP1, a novel poly (ADP-ribose) polymerase inhibitor.

Giri P, Gupta L, Singh S, Patel N, Srinivas NR, Srivastva BK, Desai RC, Patel PR.

Xenobiotica. 2019 Oct;49(10):1164-1172. doi: 10.1080/00498254.2018.1546916. Epub 2019 Jan 8.

PMID:
30488748
23.
24.

Use of Cocktail Probe Drugs for Indexing Cytochrome P450 Enzymes in Clinical Pharmacology Studies - Review of Case Studies.

Giri P, Patel H, Srinivas NR.

Drug Metab Lett. 2019;13(1):3-18. doi: 10.2174/1872312812666181119154734.

PMID:
30451124
25.

Incurred sample reanalysis in drug discovery bioanalysis.

Giri P, Patel N, Joshi V, Giri S, Srinivas NR.

Biomed Chromatogr. 2019 Mar;33(3):e4430. doi: 10.1002/bmc.4430. Epub 2018 Dec 6.

PMID:
30412644
26.

Antiretroviral concentrations and surrogate measures of efficacy in the brain tissue and CSF of preclinical species.

Srinivas N, Rosen EP, Gilliland WM Jr, Kovarova M, Remling-Mulder L, De La Cruz G, White N, Adamson L, Schauer AP, Sykes C, Luciw P, Garcia JV, Akkina R, Kashuba ADM.

Xenobiotica. 2019 Oct;49(10):1192-1201. doi: 10.1080/00498254.2018.1539278. Epub 2018 Dec 17.

PMID:
30346892
27.

ODM-203, a Selective Inhibitor of FGFR and VEGFR, Shows Strong Antitumor Activity, and Induces Antitumor Immunity.

Holmström TH, Moilanen AM, Ikonen T, Björkman ML, Linnanen T, Wohlfahrt G, Karlsson S, Oksala R, Korjamo T, Samajdar S, Rajagopalan S, Chelur S, Narayanan K, Ramachandra RK, Mani J, Nair R, Gowda N, Anthony T, Dhodheri S, Mukherjee S, Ujjinamatada RK, Srinivas N, Ramachandra M, Kallio PJ.

Mol Cancer Ther. 2019 Jan;18(1):28-38. doi: 10.1158/1535-7163.MCT-18-0204. Epub 2018 Oct 9.

PMID:
30301864
28.

Review of Clinical Pharmacokinetics of Avibactam, A Newly Approved non-β lactam β-lactamase Inhibitor Drug, In Combination Use With Ceftazidime.

Giri P, Patel H, Srinivas NR.

Drug Res (Stuttg). 2019 May;69(5):245-255. doi: 10.1055/a-0748-5548. Epub 2018 Oct 8. Review.

PMID:
30296806
29.

Telomere length, telomerase reverse transcriptase promoter mutations, and melanoma risk.

Rachakonda S, Kong H, Srinivas N, Garcia-Casado Z, Requena C, Fallah M, Heidenreich B, Planelles D, Traves V, Schadendorf D, Nagore E, Kumar R.

Genes Chromosomes Cancer. 2018 Nov;57(11):564-572. doi: 10.1002/gcc.22669. Epub 2018 Sep 11.

PMID:
30203894
30.

A pilot randomized controlled trial to compare the effectiveness of two 14-day primaquine regimens for the radical cure of vivax malaria in South India.

Saravu K, Tellapragada C, Kulavalli S, Xavier W, Umakanth S, Brahmarouphu G, Srinivas NK, Channabasavaiah JP, Bava A, Saadi AV, Guddattu V, Satyamoorthy K, Bhat K.

Malar J. 2018 Sep 3;17(1):321. doi: 10.1186/s12936-018-2472-5.

31.

Optimization of USSP duration for enhanced corrosion resistance of AA7075.

Pandey V, Singh JK, Chattopadhyay K, Srinivas NCS, Singh V.

Ultrasonics. 2019 Jan;91:180-192. doi: 10.1016/j.ultras.2018.08.011. Epub 2018 Aug 17.

PMID:
30146321
32.

In Vitro Drug-Drug Interaction Potential of Sulfoxide and/or Sulfone Metabolites of Albendazole, Triclabendazole , Aldicarb, Methiocarb, Montelukast and Ziprasidone.

Giri P, Gupta L, Naidu S, Joshi V, Patel N, Giri S, Srinivas NR.

Drug Metab Lett. 2018;12(2):101-116. doi: 10.2174/1872312812666180816164626.

33.

TERT promoter mutation subtypes and survival in stage I and II melanoma patients.

Andrés-Lencina JJ, Rachakonda S, García-Casado Z, Srinivas N, Skorokhod A, Requena C, Soriano V, Kumar R, Nagore E.

Int J Cancer. 2019 Mar 1;144(5):1027-1036. doi: 10.1002/ijc.31780. Epub 2018 Oct 4.

PMID:
30070694
34.

Identification and preclinical characterization of a novel and potent poly (ADP-ribose) polymerase (PARP) inhibitor ZYTP1.

Jain MR, Mohapatra J, Bandhyopadhyay D, Chatterjee A, Ghoshdastidar K, Patel D, Patel A, Bhayani H, Srivastava BK, Shedage SA, Kadam P, Sundar R, Patel H, Giri P, Patel P, Gupta L, Srinivas NR, Patel PR, Desai RC.

Cancer Chemother Pharmacol. 2018 Oct;82(4):635-647. doi: 10.1007/s00280-018-3653-1. Epub 2018 Jul 25.

PMID:
30046848
35.

Telomere length and survival in primary cutaneous melanoma patients.

Rachakonda S, Srinivas N, Mahmoudpour SH, Garcia-Casado Z, Requena C, Traves V, Soriano V, Cardelli M, Pjanova D, Molven A, Gruis N, Nagore E, Kumar R.

Sci Rep. 2018 Jul 19;8(1):10947. doi: 10.1038/s41598-018-29322-9. Erratum in: Sci Rep. 2018 Dec 14;8(1):17963.

36.

Central Nervous System Infections Caused by Mycobacterium abscessus: Ventricular Shunt Infection in Two Pediatric Patients and Literature Review.

Lamb GS, Del Valle Mojica C, Srinivas N, Starke J.

Pediatr Infect Dis J. 2019 May;38(5):e99-e104. doi: 10.1097/INF.0000000000002146.

PMID:
30001229
37.

Prediction of Human Pharmacokinetics of Bendamustine from Preclinical Species Pharmacokinetics Based on Normalizing Time Course Profiles.

Jairam RK, Mallurwar SR, Sulochana SP, Chandrasekar DV, Bhamidipati RK, Richter W, Srinivas NR, Mullangi R.

Drug Res (Stuttg). 2019 Jan;69(1):32-39. doi: 10.1055/a-0640-8977. Epub 2018 Jul 11.

PMID:
29996173
38.

Carbamylated Hemoglobin can Differentiate Acute Kidney Injury from Chronic Kidney Disease.

Naresh Y, Srinivas N, Vinapamula KS, Pullaiah P, Rao PVLNS, Sivakumar V.

Indian J Nephrol. 2018 May-Jun;28(3):187-190. doi: 10.4103/ijn.IJN_341_16.

39.

Impact of collagen-induced arthritis on the pharmacokinetic disposition of voriconazole, a widely used antifungal agent: in vitro and in vivo investigations in DBA/1J mice.

Giri P, Delvadia P, Gupta L, Trivedi P, Patel N, Sharma M, Singh J, Chatterjee A, Kadam S, Srinivas NR.

Xenobiotica. 2019 Jun;49(6):698-707. doi: 10.1080/00498254.2018.1485989. Epub 2018 Jul 30.

PMID:
29873579
40.

Standard curve range for clinical sample analysis of oral bioavailability/bioequivalence studies: dilemma, introspection and strategies.

Tripathi P, Patel H, Kulshrestha T, Srinivas NR.

Bioanalysis. 2018 May 1;10(10):717-722. doi: 10.4155/bio-2018-0008. Epub 2018 May 17. No abstract available.

PMID:
29771145
41.

Two Decades-Long Journey from Riluzole to Edaravone: Revisiting the Clinical Pharmacokinetics of the Only Two Amyotrophic Lateral Sclerosis Therapeutics.

Dash RP, Babu RJ, Srinivas NR.

Clin Pharmacokinet. 2018 Nov;57(11):1385-1398. doi: 10.1007/s40262-018-0655-4. Review.

PMID:
29682695
42.

Rats and rabbits as pharmacokinetic screening tools for long acting intramuscular depots: case study with paliperidone palmitate suspension.

Patel H, Patel P, Modi N, Patel P, Wagh Y, George A, Desai N, Srinivas NR.

Xenobiotica. 2019 Apr;49(4):415-421. doi: 10.1080/00498254.2018.1464683. Epub 2018 May 8.

PMID:
29642738
43.

Clinical Pharmacology Considerations for Development of β Lactamase Inhibitor Combination with Antibiotics.

Srinivas NR.

Drug Res (Stuttg). 2018 Sep;68(9):536-540. doi: 10.1055/a-0590-3791. Epub 2018 Apr 9.

PMID:
29631295
44.

Reduced Ketobemidone Usage in Quadratus Lumborum Block Patients After Cesarean Delivery: Clinical Pharmacology Views.

Srinivas NR.

Anesth Analg. 2018 Jul;127(1):311. doi: 10.1213/ANE.0000000000003369. No abstract available.

PMID:
29624532
45.

Lack of Translatable Proinflammatory Cytokines in Cerebrospinal Fluid in Rats With Increased Hyperalgesia With or Without Fentanyl Treatment.

Srinivas NR.

Anesth Analg. 2018 Jun;126(6):2150. doi: 10.1213/ANE.0000000000002895. No abstract available.

PMID:
29517569
46.

Limited Sampling Strategy for Accurate Prediction of Pharmacokinetics of Saroglitazar: A 3-point Linear Regression Model Development and Successful Prediction of Human Exposure.

Joshi SN, Srinivas NR, Parmar DV.

Clin Ther. 2018 Mar;40(3):456-468.e1. doi: 10.1016/j.clinthera.2018.01.016. Epub 2018 Feb 26.

PMID:
29496320
47.

Pharmacology of Pimasertib, A Selective MEK1/2 Inhibitor.

Srinivas NR.

Eur J Drug Metab Pharmacokinet. 2018 Aug;43(4):373-382. doi: 10.1007/s13318-018-0466-x. Review.

PMID:
29488172
48.

Clinical Pharmacokinetics and Pharmacodynamics of Drugs in the Central Nervous System.

Srinivas N, Maffuid K, Kashuba ADM.

Clin Pharmacokinet. 2018 Sep;57(9):1059-1074. doi: 10.1007/s40262-018-0632-y. Review.

49.

Letter: high oral dose of taurine for portal hypertension in cirrhotic patients-some clinical pharmacology considerations.

Srinivas NR.

Aliment Pharmacol Ther. 2018 Mar;47(6):861-862. doi: 10.1111/apt.14513. No abstract available.

50.

Barriers and enablers to adoption of intrauterine device as a contraceptive method: A multi-stakeholder perspective.

Mishra N, Panda M, Pyne S, Srinivas N, Pati S, Pati S.

J Family Med Prim Care. 2017 Jul-Sep;6(3):616-621. doi: 10.4103/2249-4863.222028.

Supplemental Content

Loading ...
Support Center